BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) Revenue
Annual & quarterly revenue history · segment & region breakdown
BMRN · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBioMarin Pharmaceutical Inc. trailing twelve-month (TTM) revenue is $3.24B, an increase of 12.87% year-over-year from $3.22B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $3.22B | +$0.37B | +12.87% |
| 2024-12-31 | $2.85B | +$0.43B | +17.97% |
| 2023-12-31 | $2.42B | +$0.32B | +15.42% |
| 2022-12-31 | $2.10B | +$0.25B | +13.53% |
| 2021-12-31 | $1.85B | -$0.01B | -0.76% |
| 2020-12-31 | $1.86B | +$0.16B | +9.18% |
| 2019-12-31 | $1.70B | +$0.21B | +14.27% |
| 2018-12-31 | $1.49B | +$0.18B | +13.52% |
| 2017-12-31 | $1.31B | +$0.20B | +17.62% |
| 2016-12-31 | $1.12B | +$0.23B | +25.50% |
Compare revenue vs peers
BiotechnologyCompare BMRN revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BioMarin Pharmaceutical Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BioMarin Pharmaceutical Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from BioMarin Pharmaceutical Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BMRN revenue · 4 questionsBMRN's trailing twelve-month (TTM) revenue is $3.24B. That is an increase of 12.87% year-over-year from $3.22B in FY2025.
▸ Source: FMP · BioMarin Pharmaceutical Inc. SEC filings · GAAP · BioMarin Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026